Relevant bibliographies by topics / Combination of drugs

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Combination of drugs'

Author: Grafiati
Published: 28 May 2022
Last updated: 22 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Combination of drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Combination of drugs"

1

Gever, Marcy Portnoff. "Combination drugs…" Nursing 36, no. 7 (2006): 63. http://dx.doi.org/10.1097/00152193-200607000-00050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

GEVER, MARCY PORTNOFF. "Combination drugs…" Nursing 36, no. 9 (2006): 70. http://dx.doi.org/10.1097/00152193-200609000-00049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

GEVER, MARCY PORTNOFF. "Combination drugs…" Nursing 36, no. 10 (2006): 77. http://dx.doi.org/10.1097/00152193-200610000-00050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

GEVER, MARCY PORTNOFF. "Combination drugs…" Nursing 37, no. 1 (2007): 71. http://dx.doi.org/10.1097/00152193-200701000-00051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

GEVER, MARCY PORTNOFF. "Combination drugs…" Nursing 37, no. 2 (2007): 71. http://dx.doi.org/10.1097/00152193-200702000-00049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

GEVER, MARCY PORTNOFF. "Combination drugs…" Nursing 35, no. 8 (2005): 76. http://dx.doi.org/10.1097/00152193-200508000-00057.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

GEVER, MARCY PORTNOFF. "Combination drugs…" Nursing 35, no. 10 (2005): 73. http://dx.doi.org/10.1097/00152193-200510000-00053.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

GEVER, MARCY PORTNOFF. "Combination drugs …" Nursing 36, no. 1 (2006): 25. http://dx.doi.org/10.1097/00152193-200601000-00017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

GEVER, MARCY PORTNOFF. "Combination drugs…" Nursing 36, no. 2 (2006): 69. http://dx.doi.org/10.1097/00152193-200602000-00054.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

GEVER, MARCY PORTNOFF. "Combination drugs…" Nursing 36, no. 4 (2006): 67. http://dx.doi.org/10.1097/00152193-200604000-00052.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Combination of drugs"

1

Shi, Yun, and 施昀. "Escalation with overdose control for phase I drug-combination trials." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hub.hku.hk/bib/B49799733.

Full text
Abstract:
The escalation with overdose control (EWOC) method is a popular modelbased dose finding design for phase I clinical trials. Dose finding for combined drugs has grown rapidly in oncology drug development. A two-dimensional EWOC design is proposed for dose finding with two agents in combination based on a four-parameter logistic regression model. During trial conduct, the posterior distribution of the maximum tolerated dose (MTD) combination is updated continuously in order to find the appropriate dose combination for each cohort of patients. The probability that the next dose combination exceeds the MTD combination can be controlled by a feasibility bound, which is based on a prespecified quantile for the MTD distribution such as to reduce the possibility of over-dosing. Dose escalation, de-escalation or staying at the same doses is determined by searching the MTD combination along rows and columns in a two-drug combination matrix. Simulation studies are conducted to examine the performance of the design under various practical scenarios, and illustrate it with a trial example.<br>published_or_final_version<br>Statistics and Actuarial Science<br>Master<br>Master of Philosophy
APA, Harvard, Vancouver, ISO, and other styles
2

Almoyad, Muhammad. "Synergism from combination of targeted therapy and phytochemicals in colorectal cancer." Thesis, The University of Sydney, 2018. http://hdl.handle.net/2123/18161.

Full text
Abstract:
Colorectal cancer is the second most common cancer in women and third in men, accounting for 9.7 % of all cancers incidence. Oxaliplatin is a platinum-based anticancer drug used typically in combination with folinic acid and 5-fluorouracil for treatment against colorectal cancer. However, numerous side effects such as nausea and vomiting, GI toxicity, anaemia, immunodeficiency, ototoxicity, nephrotoxicity, and neurotoxicity are associated with its use. These can be decreased by lowering dose of oxaliplatin. Phytochemicals that can act as antioxidants have been used by people in treatment against cancer throughout human history because of their low toxicity and the ease in availability. Besides providing protection against cancer, they can also kill cancer cells. Studies show that chemopreventive agents would boost activity of anticancer drugs and thus improve treatment outcome. In this study, resveratrol, thymoquinone, capsaicin and quercetin were applied to four human colorectal cancer cell lines HT-29, Caco-2, Lim-1215 and Lim-2405 in combination with platinum drugs cisplatin and oxaliplatin using three sequences of administration (0/0 h, 0/4 h and 4/0 h). Activity of compounds alone and in combination were determined using MTT reduction assay. Combination index was used as a measure of combined drug action. Studies on cellular accumulation, platinumDNA binding, DNA damage and proteomics were carried out to obtain mechanistic insights. In HT-29 cell line all sequences of administration produced antagonism at lower concentration (ED50). In Caco-2 cell line, bolus combination of cisplatin with resveratrol was found to produce moderate synergistic effect at all concentrations. In Lim-2405 cell line, combination of cisplatin with quercetin was found to produce most synergistic outcome. As applied to oxaliplatin, its combination with quercetin was found to produce most synergistic outcomes in Caco-2 cell line. Combination of oxaliplatin and capsaicin was most synergistic in Lim-2405 cell line. Results on PtDNA binding showed that synergistic effect was associated with higher platinumDNA binding. In proteomics study, 16 proteins belonging to different functional groupings were found to undergo changes in expression as a result of treatment with synergistic combinations.
APA, Harvard, Vancouver, ISO, and other styles
3

Al, Onazi Fahad Nasser. "Platinum drugs given in combination with phytochemicals to enhance platinum action." Thesis, The University of Sydney, 2017. http://hdl.handle.net/2123/18971.

Full text
Abstract:
This study focused on the sequenced combinations of platinum drugs cisplatin and oxaliplatin and four phytochemicals celastrol, guggulsterone, garcinol and ellagic acid administered to human ovarian lines A2780, A2780cisR and A2780ZD0473R. Among the phytochemicals, celastrol is most active having comparable activity against all the three ovarian tumour models. As applied to binary combinations of platinum drugs and the phytochemicals, it was found that generally synergism was greater at higher concentrations (ED75 and ED90) of drugs than at lower concentrations (ED50) in all three cell lines. Often 0/0 h and 0/4 h sequences of administration were found to be more synergistic, giving support to the idea that pre-treatment or concurrent with the phytochemicals have served to activate the cancer cells towards assault by the platinum drugs. The reduced accumulation of platinum in the cisplatin resistant cell line A2780cisR as compared to the cisplatin sensitive cell line A2780, gives support to the concept that the reduced platinum accumulation is the principal mechanism by which the cisplatin resistant cell line A2780cisR cell line resist the platinum drugs action. The absence of any visible DNA band after interaction of A2780 cells with ellagic acid indicates total DNA damage so that the phytochemical is most damaging to DNA in A2780 cells. The results of the present study showed the levels of reduced form of glutathione (GSH) in the resistant cell line A2780cisR were higher than the parent cell line A2780, irrespective of whether the cells were treated with a single agent (cisplatin, oxaliplatin, or ellagic acid) or in combination, giving support to the idea that the higher levels of glutathione serve to be one of the central mechanisms of cisplatin resistance in ovarian cancer cells.
APA, Harvard, Vancouver, ISO, and other styles
4

Bali, Hana. "Synergism from combination of platinum drugs and selected phytochemicals in colorectal cancer." Thesis, The University of Sydney, 2018. http://hdl.handle.net/2123/18798.

Full text
Abstract:
Colorectal cancer is the second most leading cause of death among all reported cancer mortality. Chemotherapy is the treatment of choice to treat metastasized colorectal cancer patients. Combined administration of drugs having different mechanism of actions has been demonstrated better efficacy than conventional monotherapy. Epidemiological data suggests that consumption of phytochemicals has a great impact in prevention and treatment of colorectal cancer. In this study four phytochemicals including curcumin, colchicine, EGCG and taxol were combined with cisplatin and oxaliplatin in a binary mode at three different concentrations and sequence of administrations against four different colorectal cancer cell lines (HT-29, CACO-2, LIM-1215 and LIM-2405). When oxaliplatin is combined with curcumin or EGCG, the cytotoxic outcome is more synergistically effective than the combination of cisplatin with either phytochemicals in a binary combination. However, cisplatin in combination with colchicine showed greater synergism than that of oxaliplatin with colchicine. Observed synergisms of the combinations were found to be correlated with platinumDNA binding and cellular accumulations of platinum. DNA damage study indicated that antagonistic combinations were less damaging towards DNA. Proteomic study revealed eleven proteins which displayed significant changes in expression following different drug treatments which were: NPM, ACTB, TBB5, HSP7C, K2CB, GSTP1, GRP78, PSB6, COF1, IDHC and K1C18. Among these proteins NPM and ACTB was considered as antiapoptotic whereas IDHC and K1C18 believed to be proapoptotic.
APA, Harvard, Vancouver, ISO, and other styles
5

Yang, Jianning. "Mechanism-Based Computational Models to Study Pharmacological Actions of Anticancer Drugs." The Ohio State University, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=osu1249622434.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Siau, Hong. "The effects of antifungal drugs in combination on the growth of Candida species." Thesis, University of Cambridge, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.359415.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kaelen, Mendel. "The psychological and human brain effects of music in combination with psychedelic drugs." Thesis, Imperial College London, 2017. http://hdl.handle.net/10044/1/55900.

Full text
Abstract:
This research investigated how psychedelics and music work together in the brain and modulate subjective experience. Chapter 1 highlighted the prominent role of music in psychedelic therapy in the 1950s and 1960s, and how music continues to be used in modern psychotherapeutic trials with psychedelics. Although ‘psychedelic therapy’ shows promising findings for mental health care, little is known empirically about the therapeutic functions of music. The primary objective of this thesis was to address this knowledge gap, via studying the effects of psychedelics and music on human brain function in healthy volunteers, and via studying the subjective experience of music, both in healthy volunteers and in patients undergoing psychedelic therapy. Study 1 (Chapter 3) demonstrated intensified music-evoked emotions under the classic psychedelic LSD, including emotions of ‘wonder’ and ‘transcendence’. In subsequent work (study 2, Chapter 4), increased activation in the inferior frontal gyrus and the precuneus to the timbre features in the music, was associated with increased music-evoked emotions of wonder. Study 3 (Chapter 5) demonstrated that LSD and music interact to enhance information flow from the parahippocampus to the visual cortex, and that this effect correlated with increased complex mental imagery and autobiographical memories. Study 4 (Chapter 6), showed that music has a substantial influence on the therapeutic experience with psilocybin in patients with depression, and the quality of the music-experience predicted peak experiences and insightfulness during sessions, and reductions in depression after sessions. These findings support the hypothesis that the music-experience is intensified under psychedelics, and the widely-held view that this effect may be therapeutically significant. Possible brain mechanisms and therapeutic mechanisms are discussed in Chapter 7, but further research is warranted to better understand these mechanisms, and to learn how music can be best used in psychedelic therapy.
APA, Harvard, Vancouver, ISO, and other styles
8

Cronin-Fine, Drew. "Pricing and reimbursement challenges for fixed dose combination cardiovascular drugs and intravenous oncologies." Thesis, Massachusetts Institute of Technology, 2012. http://hdl.handle.net/1721.1/72918.

Full text
Abstract:
Thesis (S.M.)--Harvard-MIT Program in Health Sciences and Technology, 2012.<br>Cataloged from PDF version of thesis.<br>Includes bibliographical references (p. 63-67).<br>Over the past ten years there has been increasing public concern regarding the rising costs of pharmaceuticals. Drug expenditure is the fastest growing sector of healthcare costs in the United States. The structure of the U.S. healthcare system allows pharmaceutical companies to freely price their drugs. Then payers decide whether and how to cover these drugs. Payers have at their disposal several utilization management tools, such as tiering and prior authorizations, to steer their members to less costly drugs. However, the ability of payers to implement these tools varies significantly depending on whether the drug is covered under the pharmaceutical benefit / Medicare Part D provisions of healthcare plans or the medical benefit / Medicare Part B provisions. Drugs covered under the pharmaceutical benefit / Part D are distributed via retail pharmacies and, in general, are oral pills. Drugs covered under the medical benefit / Part B are physician administered drugs and, in general, are injectables or intravenous drugs. As pharmaceutical companies increasingly price their drugs at higher and higher levels, payers must take a drug's pricing into account when determining how to cover these drugs. This thesis assesses the role pricing plays in how a drug is covered. Two different classes of drugs were chosen to examine this topic: fixed dose combination (FDC) cardiovascular drugs and intravenous oncologies. FDC cardiovascular drugs were chosen because they are covered under the pharmacy benefit / Part D and are considered to have questionable efficacious value over their individual drug components. Intravenous oncologies were chosen because they are covered under the medical benefit / Part B and represent a highly politicized therapy area. These two therapy areas are illustrative of strongly contrasting classes of drugs. Literature review and public sources were used to obtain prices for the select cardiovascular FDCs and oncologies. Medicare's Formulary Finder was used to obtain the coverage level for the cardiovascular FDCs. This preliminary information showed that the most expensive of the select FDCs, Caduet, has the worst coverage. The literature review suggested that Provenge and Avastin, the most expensive of the select oncologies, had difficulty obtaining coverage. To confirm these results, interviews were conducted with a variety of payers. These interviews focused on what factors went into the coverage decision-making process for cardiovascular FDCs and intravenous oncologies. Interviews were also conducted with an oncologic distributor to determine distributors' impact on price. We hypothesized that price was the driving reason for Caduet's, Provenge's, and Avastin's relatively poor coverage. However, our hypothesis was not entirely confirmed. Payers confirmed that price and contracting were the driving factors for Caduet's relatively poor coverage, but they indicated that the situation was not as simple for the intravenous oncologies. Although price does play a small role in the coverage decision-making process for intravenous oncologies, other factors such as public policies and the unmet need in the therapy area drive coverage decisions more than price. Additionally, payers indicated that they lack the ability to steer members to less costly intravenous oncologies due to the drug acquisition and reimbursement structure of the medical benefit. Consequently, payers are beginning to utilize new techniques such as specialty pharmacies to help control utilization of these products. Also, other organizations such as certain oncologic distributors are attempting to implement cost-effective guidelines for intravenous oncologies. Our results have significant implications for what pharmaceutical companies should be considering when pricing their drugs, and highlight the pricing and coverage issues in the current healthcare system's structure that payers and other organizations are facing.<br>by Drew Cronin-Fine.<br>S.M.
APA, Harvard, Vancouver, ISO, and other styles
9

McLeese, Michelle Frances. "Increases in Drug and Alcohol Problems: A Combination of Job and Home Stressors?" Thesis, Virginia Tech, 2005. http://hdl.handle.net/10919/30846.

Full text
Abstract:
Using data from the National Comorbidity Survey (NCS) from the Fall of 1990 to the Spring of 1992 among respondents between the ages of 15 and 54 in 48 of the contiguous United States, this paper hypothesized an increase in serious drug problems and serious alcohol problems when a combination approach was used regarding home and work stressors. Results indicate support for the hypotheses that the combination of home and work stressors leads to an increase in both serious drug and alcohol problems (each measured separately). These findings are important especially since they suggest that stressors from home affecting work are significant and positively related to problems with both alcohol and drugs and stressors from work affecting home are not. In addition to demographic controls and stress scales of work and home, the model takes into account other possible explanations. These include past traumatic or recent life events that are considered high in stress, the family background of the parents of the respondents with regard to past psychiatric disorders, and the comorbidity of the respondents themselves. Results imply that stressors from home affecting work are significant and matter more than work stressors affecting home in every model. This research improves upon previous research by both exploring the inter-relationship between home and work stress and controlling for alternative explanations. Although more research needs to be carried out in the area of â home stressors,â these results suggest previous conflicting findings within the work stress literature may be due in part to too narrow of a focus on stressors at the workplace or related to the job environment separate from home stressors.<br>Master of Science
APA, Harvard, Vancouver, ISO, and other styles
10

Soble, Michelle Joy 1961. "THE EFFECTS OF GLUTATHIONE DEPLETION BY L-BUTHIONINE-(S,R) SULFOXIMINE ON THE ANTITUMOR EFFICACY OF MODEL SULFHYDRYL-DEPENDENT ANTICANCER AGENTS (BSO)." Thesis, The University of Arizona, 1986. http://hdl.handle.net/10150/276859.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Combination of drugs"

1

Jerzy, Majkowski, ed. Antiepileptic drugs: Combination therapy and interactions. Cambridge University Press, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Natale, Valerie. Drug discovery technology: A combination of opportunities. Business Communications Co., 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wrotnowski, Cort. Drug discovery technologies: A combination of opportunities. Business Communications Co., 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gopalaswamy, Smita. Combination products: Regulatory challenges and successful product developement. CRC Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lyu, SuPing, and Ronald Alan Siegel. Drug-device combinations for chronic diseases. John Wiley & Sons, Inc., 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hemaiswarya, Shanmugam, Pranav Kumar Prabhakar, and Mukesh Doble. Herb-Drug Combinations. Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-5125-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

S, Tatro David, ed. Drug interaction facts: The authority on drug interactions. 2nd ed. Facts and Comparisons, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

United States. Congress. Senate. Committee on Appropriations. Subcommittee on Departments of Labor, Health and Human Services, Education, and Related Agencies, ed. HIV/AIDS drugs: Funding implications of new combination therapies for federal and state programs : report to the Subcommittee on Labor, Health and Human Services, and Education, Committee on Appropriations, U.S. Senate. The Office, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

H, Messerli Franz, and Opie Lionel H, eds. Combination drug therapy for hypertension. Author's Pub. House, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

S, Tatro David, ed. Drug interaction facts. 2nd ed. Facts and Comparisons, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Combination of drugs"

1

Perno, C. F., A. Bergamini, G. Milanese, et al. "Cytokines Modulate HIV Replication and the Activity of Antiviral Drugs in Cells of Monocyte/Macrophage Lineage." In Combination Therapies. Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ackland, Stephen P., and Rosemary Kimbell. "Antifolates in Combination Therapy." In Antifolate Drugs in Cancer Therapy. Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-725-3_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Beaman, Jon V., and Roisin Wallace. "Combination Products/Drugs in Devices." In Handbook of Stability Testing in Pharmaceutical Development. Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-85627-8_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lodola, Alberto. "Nonclinical Development of Combination Drugs." In Methods in Molecular Biology. Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7172-5_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sarin, Prem S., Allan Goldstein, S. Agrawal, and Paul Zamecnik. "Use of Drugs Targeted to Inhibit Different Stages of the HIV Life Cycle in the Treatment of AIDS." In Combination Therapies. Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Garcha, Shilpa Chugh, and Sanjay Kalra. "Fixed Combination Anti-obesity Medications." In Drugs for Medical Management of Obesity. Springer Nature Singapore, 2025. https://doi.org/10.1007/978-981-96-1651-0_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lodola, Alberto. "Developing Combination Drugs in Preclinical Studies." In Methods in Molecular Biology. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-849-2_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nakamura, Haruo. "Management of Primary Hyperlipidemia with Combination Therapy." In Drugs Affecting Lipid Metabolism. Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-0311-1_58.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rahn, K. H. "Principles in the Combination of Antihypertensive Drugs." In Pharmacology of Antihypertensive Therapeutics. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74209-5_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Amaro, Sergio, Xabier Urra, and Ángel Chamorro. "Toward Effective Combination Therapy and Pleiotropic Drugs." In Springer Series in Translational Stroke Research. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-45345-3_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Combination of drugs"

1

Yu, Ruixia, Hualing Chen, Tianning Chen, and Hairong Wang. "Topology Optimization of MEMS-Based Biodegradable Controlled Drug Delivery System for Combination Therapy." In 2007 First International Conference on Integration and Commercialization of Micro and Nanosystems. ASMEDC, 2007. http://dx.doi.org/10.1115/mnc2007-21175.

Full text
Abstract:
MEMS-based biodegradable controlled release system with micro multi-chambers can respectively enclose two drugs in different chambers to realize a combination therapy. In order to synchronously obtain the linear release of two drugs, it is necessary to completely investigate the topology optimization of the system. This paper introduces the theory of multi-objective topology optimization into MEMS-based biodegradable controlled release system for the combination therapy. Furthermore, a new method of CA-based evolutionary structural optimization (CA-ESO) is presented to accomplish the topology optimization of this controlled release system. The result shows that the optimized drug delivery system can achieve the objective of the synchronizing linear release for two drugs. The conclusion illustrates that the CA-ESO method proposed in this paper is validity for the topology optimization of MEMS-based biodegradable controlled release system.
APA, Harvard, Vancouver, ISO, and other styles
2

Anggrainingsih, Rini, Nach Rowi Khoirudin, and Haryono Setiadi. "Discovering drugs combination pattern using FP-growth algorithm." In 2017 4th International Conference on Electrical Engineering, Computer Science and Informatics (EECSI). IEEE, 2017. http://dx.doi.org/10.1109/eecsi.2017.8239203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"Drugs Combination for Treating Parthenium Dermatitis: A Case Study." In International Conference on Biological, Environment and Food Engineering. International Institute of Chemical, Biological & Environmental Engineering, 2014. http://dx.doi.org/10.15242/iicbe.c814025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ansbro, E., S. Masri, D. Prieto-Merino, et al. "Fixed dose combination drugs for cardiovascular disease in Lebanon." In MSF Scientific Days International 2022. MSF-USA, 2022. http://dx.doi.org/10.57740/8697-vn33.

Full text
Abstract:
INTRODUCTION Cardiovascular disease (CVD) is the leading cause of death and disability globally, including in humanitarian contexts. Fixed-dose combination (FDC) drugs are cost-effective for primary and secondary prevention of CVD. From 2012 until the end of 2020, MSF provided care for CVD patients from Syrian refugee and host populations in primary care clinics in Tripoli, north Lebanon. In this implementation study, we assessed whether FDC use is linked with adherence to CVD medications and treatment simplification in a humanitarian setting. METHODS Our prospective, before-and-after cohort study followed CVD patients in MSF clinics in Lebanon during two consecutive six month periods. Eligible patients, enrolled February-May 2019, were switched to Trinomia® FDC (atorvastatin 20mg, aspirin 100 mg, ramipril 2.5/5/10/mg) after six months’ usual care. During the study, the Covid-19 pandemic, an economic crisis, and clinic closures occurred. Descriptive and regression analyses compared key outcomes: medication adherence, non-high density lipoprotein cholesterol (non-HDL-C) levels, and systolic blood pressure (SBP) control, at six and twelve months. We performed intention-to-treat analyses and secondary analyses of non-switchers. ETHICS This study was approved by the MSF Ethics Review Board, the LSHTM Research Ethics Committee, and the Lebanese American University’s Institutional Review Board. RESULTS Of 521 enrolled patients, 460 (88.3%) were retained at six months and 418 (80.3%) switched to FDC. By month 12, 84% of switched patients remained on FDC (n=351), 8.1% (n=34) discontinued, and 7.9% (n=33) were lost to follow-up. Among the 385 who initially switched and remained in the study at 12 months, total adherence improved by 23% from 63% (95% confidence intervals (CI) 0.58-0.68) at month six to 86% (95% CI 0.82-0.90) at month 12. Mean non-HDL-C levels dropped 0.28 millimoles/litre (mmol/L; 95% CI -0.38 to -0.1; p=0.000) from 2.39 (95% CI 2.26 - 2.51) to 2.11 mmol/L (95% CI 2.00 - 2.22); mean SBP dropped 3.07 mmHg (95% CI -4.76 to -1.38; p= 0004) from 132.7 (95% CI 130.8 - 134.6) to 129.7 mmHg (95% CI 127.9 - 131.5). Among non-switchers, total adherence was lower and improvements in clinical outcomes were less pronounced. CONCLUSION Implementing a CVD secondary prevention FDC was associated with better adherence and intermediate clinical outcomes inan MSF primary care clinic in Lebanon. Further operational experience is needed to ascertain how best to integrate and sustain CVD FDC’s in humanitarian operations. MSF could advocate for their broader use with other humanitarian actors and within public health systems of crisis-affected countries. CONFLICTS OF INTEREST None declared.
APA, Harvard, Vancouver, ISO, and other styles
5

Ansbro, E., S. Masri, D. Prieto-Merino, et al. "Fixed dose combination drugs for cardiovascular disease in Lebanon." In MSF Scientific Days International 2022. MSF-USA, 2022. http://dx.doi.org/10.57740/mzsh-8t29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Boulle, P. "Fixed dose combination drugs for cardiovascular disease in Lebanon." In MSF Scientific Days International 2022. MSF-USA, 2022. http://dx.doi.org/10.57740/jfe7-0d04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Korol, A. P., V. O. Hnenna, and O. O. Hovorushchenko. "Combination of drugs for the treatment of major depressive disorder." In TRENDS AND AREAS OF HEALTHCARE DEVELOPMENT IN THE EU AND UKRAINE. Baltija Publishing, 2024. https://doi.org/10.30525/978-9934-26-514-3-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mustafa, Fadhil Ilham, Nurfitri Bustamam, and Andri Pramesyanti. "Association between Compliance Level on Fixed-Dose Combination Antiretroviral Drug and CD4 Level among HIV Patients." In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.02.03.

Full text
Abstract:
Background: People living with HIV / AIDS (PLWHA) have weak immune systems and are prone to infection. Therefore, PLWHA must take antiretroviral (ARV) to maintain their immunity. This study aimed to determine the relationship between the level of adherence to taking ARV fixed-dose combination (FDC) drugs and CD4 levels of HIV patients. Subjects and Method: This was a cross-sectional study conducted at Pengayoman Cipinang Hospital, Indonesia, in 2018. Total of 91 HIV patient over 17 years of age, had or had received FDC ARV therapy for at least 1 year, and did not experience drug-induced hepatitis were enrolled in this study. The dependent variable was CD4 level. The independent variable was level of adherence to taking ARV fixed-dose combination (FDC). The data were taken from the Voluntary Counseling and Testing Poli Pengayoman Cipinang Hospital. This study used secondary data from the Overview of HIV Care and ARV Therapy. The data were analyzed using Chi-square. Results: A total of 65.93% HIV patients had a good level of medication adherence and 79.12% had an increase of CD4 levels. There was a significant relationship between adherence to taking FDC ARV drugs and CD4 levels (OR = 6.50; 95% CI = 2.15 to 19.62; p&lt;0.001), and it was statistically significant. Conclusion: There is a significant relationship between the level of adherence to taking FDC ARV drugs and CD4 levels. Therefore, patients must receive education and support to improve adherence to taking ARV drugs. Keywords: antiretroviral, CD4, fixed-dose combination, adherence to taking medication, people with HIV / AIDS Correspondence: Fadhil Ilham Mustafa. Faculty of Medicine, Universitas Pembangunan Nasional Veteran, Jakarta. Jl. RS Fatmawati, Pondok Labu, South Jakarta. Email: fadhilimn@gmail.com. Mobile: 081283681755. DOI: https://doi.org/10.26911/the7thicph.02.03
APA, Harvard, Vancouver, ISO, and other styles
9

Farn Max Liang, Sheau, Kai Xuan Luo, Ren Ming Zhang, and Tu Sheng Lee. "Combination of tall-man lettering and symbol prefixing to improve drug identification by pharmacists." In 14th International Conference on Applied Human Factors and Ergonomics (AHFE 2023). AHFE International, 2023. http://dx.doi.org/10.54941/ahfe1003450.

Full text
Abstract:
Similar drug names can confuse pharmacists and lead to dispensing errors. A well-accepted solution to the problem is tall-man lettering, a typographic alteration to drug names. However, studies of its effectiveness have yielded mixed results. Furthermore, the potential of orthographic alterations to drug names has not been explored. Therefore, this study aims to examine the usefulness of the combination of tall-man lettering and a simple but new orthographic alteration, symbol prefixing. Twenty-six outpatient pharmacists were recruited to participate in an experiment on drug identification. The results showed that first, the accuracy of drug identification increased with tall-man lettering. Next, the response time and the number of eye fixations for the identification decreased with tall-man lettering and symbol prefixing. Finally, the number of eye fixations decreased with symbol prefixing when there was no tall-man lettering. The findings support that tall-man lettering and symbol prefixing are effective techniques for helping pharmacists identify drugs. Further research could assess the impacts of different types of typographic and orthographic alterations for alleviating the problem of drug name confusion and ultimately minimizing medication errors and ensuring patient safety.
APA, Harvard, Vancouver, ISO, and other styles
10

Oro Fernandez, M., CM Valencia Soto, JI Gutierrez Revilla, F. Perez Hernandez, and A. Tejerina. "5PSQ-090 Anticholinergic drugs and acetylcholinesterase inhibitors: a non-recommended combination." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.523.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Combination of drugs"

1

พนมวัน ณ อยุธยา, ดวงจิต, ปฏิภาณ พนมวัน ณ อยุธยา та อภิฤดี เหมะจุฑา. การสำรวจการใช้ยาของโรงพยาบาล มหาวิทยาลัยในกรุงเทพมหานครระหว่าง พ.ศ. 2523-2525 : รายงานผลการวิจัย. จุฬาลงกรณ์มหาวิทยาลัย, 1985. https://doi.org/10.58837/chula.res.1985.14.

Full text
Abstract:
The top 200 drug products most frequently dispensed in the university hospitals in Bangkok during 1980 to 1982 were identified and ranked. Paracetamol was ranked number one with the highest number of tablets dispensed while Ampicillin was ranked number one with the highest value dispensed. The top 200 drug products accounted for approximately 82 percent of the total value of drug dispensed in a year. At the same time, the drugs were classified according to their pharmacological action. Penicillins was the sub-pharmacological class with the highest value dispensed which accounted for approximately 10-12 percent of the total value of drug dispensed in a year while drug acting on the Neuro-Muscular system which accounted for approximately 25 percent of the total value of drug dispensed in a year was idenified as the pharmacological class with the highest value dispensed. Lastly, the top 200 drug products were compared with the 1981 National List of Essential Drugs. Of the top 200 drug products approximately 52 percents of them contains the generic names which are in the essential drug list. Half of the drug products which are not in the essential drug list are combination drugs.
APA, Harvard, Vancouver, ISO, and other styles
2

Silva, Gabriela, Jovânia Oliveira, Maria Eduarda Almeida, Isabela Costa, Suzane Pigossi, and Marcelo Franchin. Unlocking Synergistic Potential: Propolis in combination with pharmaceutical drugs in disease treatment and prevention. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2025. https://doi.org/10.37766/inplasy2025.4.0095.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Deng, Jianhao, jiaxing Zhang, QingXia Zhang, and Guowei Zhong. Serotonin syndrome with dextromethorphan alone and in combination with other serotonergic drugs. a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.5.0079.

Full text
Abstract:
Review question / Objective: To assess the evidence for serotonin syndrome occurring in the context of dextromethorphan administration. To assess concurrent medication to see if there are associations with 1) other serotonergic medication. Condition being studied: It is uncertain whether use of dextromethorphan alone or in therapeutic doses can cause Serotonin syndrome (SS). Also, SS by dextromethorphan has not previously been systematically reviewed. Therefore, the main aim is to present a systematic review and summary of these studies.
APA, Harvard, Vancouver, ISO, and other styles
4

Rada, Gabriel. What are the effects of using drugs packaged in unit doses to treat malaria? SUPPORT, 2017. http://dx.doi.org/10.30846/170305.

Full text
Abstract:
Millions of people contract malaria each year. The WHO currently promotes artemisinin-based combination therapy for treating uncomplicated malaria, but this may be more difficult for patients to correctly adhere to than other treatments. Packaging a course of treatment in units of a single dose may be a more effective way of ensuring that patients take the correct dosage, and thus of increasing treatment success. In this approach, drugs to be taken together are packaged adjacent to each other, sometimes with colours or other markers to show that the drugs should be taken together.
APA, Harvard, Vancouver, ISO, and other styles
5

Roh, Meejeon. Therapeutic Value of PLK1 Knockdown in Combination with Prostate Cancer Drugs in PIM-1 Overexpressing Prostate Cancer Cells. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada613551.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Roh, Meejeon. Therapeutic Value of PLK1 Knockdown in Combination with Prostate Cancer Drugs in PIM-1 Overexpressing Prostate Cancer Cells. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada582132.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Inoue, Takashi, and Mamoru Narukawa. Anti-tumor efficacy of anti-PD-1/PD-L1 antibodies in combination with other anticancer drugs in solid tumors: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.10.0004.

Full text
Abstract:
Review question / Objective: The aim of this systematic review is to compare the combination of PD-1/PD-L1 inhibitors plus other anticancer drugs and monotherapies of PD-1/PD-L1 inhibitors in terms of antitumor efficacy in the solid tumors to better inform clinical practice. To this end, the proposed systematic review will address the following question: Which is the best choice to enhance response rate in subjects with solid tumors, PD-1/PD-L1 inhibitors plus cytotoxic agents or PD-1/PD-L1 inhibitors plus other targeted anticancer drugs? Condition being studied: Cancer is the leading cause of death worldwide, accounting to approximately 9.6 million deaths worldwide in 2018. The clinical efficacy of immune checkpoint inhibitors (CPIs) including PD-1/PD-L1 inhibitors has been proven; however, it is also known that their efficacy as monotherapy is limited, with a response rate of 20% or less in solid tumors. The combination of CPIs and anticancer agents has been actively attempted in solid tumors area.
APA, Harvard, Vancouver, ISO, and other styles
8

Grueso-Navarro, Elena, Leticia Rodríguez-Alcolado, Ángel Arias, Emilio J. Laserna-Mendieta та Alfredo J. Lucendo. Influence of HLA-DQA1*05 allele in the response to anti-TNFα drugs in inflammatory bowel diseases. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.2.0076.

Full text
Abstract:
Review question / Objective: Do patients with inflammatory bowel disease and treated with any anti-TNFα drug who had the HLA-DQA1*05 allele (in heterozygosis or homozygosis) have lower response or persistence to those drugs than patients without HLA-DQA1*05 allele? Condition being studied: Inflammatory bowel diseases (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory condition that may affect any part of the digestive tract (CD) or be limited to the colon (UC). While the specific aetiology of IBD remains unknown, it is believed to involve a complex impairment in the immunity of the gut mucosa due to a combination of several genetic and environmental factors, being the microbiota one of the latest that more attraction has received in recent years. Symptoms of IBD (such as abdominal pain, diarrhoea, fever, tiredness or rectal bleeding) may be either constant or alternate between periods of limited disease activity and flares with remarkable presence of symptoms. As IBD is associated with significant morbidity and disability, pharmacological treatment is required in most cases, especially in CD, aimed at reducing the inflammatory response and attenuating the activity of the immune system. In the moderate and severe forms of the disease, therapy is usually based on immunosuppressant and/or biological drugs. Among the latest, anti-TNFα drugs (infliximab or adalimumab) are normally chosen as the initial biological therapy.
APA, Harvard, Vancouver, ISO, and other styles
9

Xu, Li, Wenjun Chen, Caijun Tian, et al. Efficacy and Safety of Chinese Herbal Medicines Combined with Chemical Drugs for Alzheimer's Disease: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.8.0007.

Full text
Abstract:
Review question / Objective: It is a common practice to apply Chinese herbal medicine with chemical drugs like donepezil to treat Alzheimer's disease in China. Therefore, the aim of this meta-analysis of randomized controlled trials is to evaluate whether this combination is more effective and safer than chemical drugs applied alone. Information sources: Literatures will be searched in China National Knowledge Infrastructure (CNKI) (http://www.cnki.net/), Wanfang Database (http://www.wanfangdata.com.cn), and the Chinese Scientific Journals Full-Text Database (VIP) (http://www.cqvip.com/) in Chinese, in the Japan Science and Technology Information Aggregator, Electronic (J-STAGE) in Japanese and English, and in PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) and Web of Science (http://apps.webofknowledge.com) in English.
APA, Harvard, Vancouver, ISO, and other styles
10

Xiang, Kemeng, Huiming Hou, and Ming Zhou. The efficacy of Cerus and Cucumis Polypeptide injection combined with Bisphosphonates on postmenopausal women with osteoporosis:A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.5.0067.

Full text
Abstract:
Review question / Objective: The aim of this review is to evaluate the effectiveness of Cerus and Cucumis Polypeptide injection combined with Bisphosphonates for postmenopausal osteoporosis. Condition being studied: Postmenopausal osteoporosis (PMOP) is a disorder of bone metabolism caused by estrogen deficiency in women after menopause, which manifests clinically as pain, spinal deformities and even fragility fractures, affecting the quality of life of patients and possibly shortening their life span. Bisphosphonates are commonly used to control and delay the progression of the disease, improve the patient's symptoms and reduce the incidence of fragility fractures. However, single drugs are still lacking in controlling the progression of the disease, and the combination of drugs is the clinical priority.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Combination of drugs' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography